Evidence map›Paper›PMID 41285480›Full record

ArticleEndocrine journal2026

Long-term effectiveness and safety of daily growth hormone therapy in Japanese children with Noonan syndrome: a post-marketing surveillance study.

Koji Muroya, Masanobu Kawai, Hiroyuki Yamagishi, Takaaki Endo, Alberto Pietropoli, Jean-Marc Ferran, Reiko Horikawa

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03435627 (Post Marketing Surveillance on Long-term Use With Norditropin®), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03435627 completednot on this map

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

TypeobservationalSponsorNovo Nordisk A/SRan2018 to 2022Enrolled71ConditionsGenetic Disorder, Noonan SyndromeArmsSomatropin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical consensus guidelines for the management of Noonan syndrome in Japan.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Koji MuroyaDepartment of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-0066, Japan.ORCID http://orcid.org/0000-0002-1810-9894
Masanobu KawaiDepartment of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka Women's and Children's Hospital, Izumi 594-1101, Japan.ORCID http://orcid.org/0000-0003-4466-1559
Hiroyuki YamagishiDivision of Pediatric Cardiology, Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID http://orcid.org/0000-0002-9756-3744
Takaaki EndoMedical Affairs Department, Novo Nordisk Pharma Ltd, Tokyo 100-0005, Japan.ORCID http://orcid.org/0009-0005-6146-6394
Alberto PietropoliDepartment of Rare Endocrine Disorders, Novo Nordisk Health Care AG, 8058 Zurich, Switzerland.
Jean-Marc FerranQualiance ApS, 1663 Copenhagen, Denmark.
Reiko HorikawaDivision of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo 157-8535, Japan.ORCID http://orcid.org/0000-0003-3429-3246

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reports on long-term safety and effectiveness of daily GH replacement therapy in Japanese children with short stature due to Noonan syndrome (NS) are limited. This post-marketing, prospective, non-interventional study (ClinicalTrials.gov NCT03435627) evaluated the long‑term safety and effectiveness of daily GH therapy in this patient population. The study took place at 22 sites in Japan during November 2017-January 2022. Seventy participants were enrolled and received Norditropin

Indexed as

Growth DisordersHormone Replacement TherapyHuman Growth HormoneNoonan SyndromeAdolescentBody HeightChildChild, PreschoolEast Asian PeopleFemaleHumansJapanMaleProduct Surveillance, PostmarketingProspective StudiesTreatment OutcomeHuman Growth HormoneChildrenGrowth hormoneJapanNoonan syndromePost-marketing product surveillance

Identifiers

PMID41285480
PMCPMC12895119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.